|by # Publications/# Citations|
|2x||Leukemia, Myelogenous, Chronic, BCR-ABL Positive|
|1x||Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative|
|Miguel A Pavlovsky||2|
|Argentine Group of Bone Marrow Transplantation||1|
|Pedro Negri Aranguren||1|
|Raimundo F Bezares||1|
Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
Title and Abstract from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Data mined from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Last MEDLINE®/PubMed® update: 1st of December 2015